Bentamapimod
Alternative Names: AS-602801; JNK inhibitor - Merck Serono; PGL-5; PGL-5001Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Merck Serono
- Developer Merck Serono; PregLem
- Class Benzothiazoles; Pyrimidines; Small molecules
- Mechanism of Action JNK mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Endometriosis
- No development reported Post-surgical adhesions
- Discontinued Multiple sclerosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Post-surgical-adhesions(Prevention) in Switzerland (PO)
- 19 Aug 2015 Bentamapimod is still in phase-II development for Endometriosis
- 01 Oct 2013 PregLem completes a phase II trial in Endometriosis in Poland (2012-001219-22)